Increased periocular pigmentation with ocular hypotensive lipid use in African Americans.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 12719085.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To report increased eyelid pigmentation as an adverse side effect associated with topical ocular hypotensive lipids in African Americans. Interventional case series. Two African-American patients with open-angle glaucoma are described in whom increased eyelid pigmentation developed 1 month to 5 months after beginning treatment with either latanoprost or bimatoprost. Latanoprost was discontinued in an African-American patient, and pigmentation gradually diminished by 3 months after cessation of latanoprost. Increased eyelid pigmentation and increased eyelash length were noted in another African-American patient after just 4 weeks on bimatoprost. An increase in eyelid pigmentation and eyelash growth is a possible complication of topical ocular hypotensive lipid therapy, even in African-American patients. The changes seems to present earlier after bimatoprost treatment then after latanoprost treatment. Cessation of these medications may lead to loss of induced pigmentation.
Medical subject headings
- Antihypertensive Agents
- Black People
- Eyelid Diseases
- Glaucoma, Open-Angle
- Hyperpigmentation
- Skin Pigmentation